Posted by Michael Wonder on 14 May 2020
Health economic assessment of Spravato in treatment resistant depression
14 May 2020 - TLV has developed a health economic knowledge base for the regions for Spravato (esketamine).
Spravato is a nasal spray that is approved for use in combination with an oral SSRI (selective serotonin reuptake inhibitor) or a SNRI (serotonin and norepinephrine reuptake inhibitor).
The approval applies to adults with treatment-resistant real depression who have not responded to at least two different treatments with anti-depressants in the ongoing moderate to severe depressive episode.
